Dr. Lang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
860 NW Washington Blvd
Hamilton, OH 45013Phone+1 513-751-2145Fax+1 513-751-2138
Summary
- Dr. Evan Lang is an oncologist in Fairfield, OH and is affiliated with multiple hospitals in the area, including Bethesda North Hospital, CMH Regional Health System, Fort Hamilton Hospital, and Mercy Health - Fairfield Hospital. He received his medical degree from The Second Military Medicine Univ and has been in practice 31 years. He specializes in hematologic oncology and is experienced in hematologic oncology, breast cancer, and general medical oncology.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2000- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1998 - 1999
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 1998
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 1995 - 1997
The Second Military Medicine UnivClass of 1986
Certifications & Licensure
OH State Medical License 1997 - 2026
KY State Medical License 2001 - 2025
IN State Medical License 2006 - 2023- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 3 citationsIdiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.Evan Lang, Frits van Rhee
Blood Reviews. 2024-03-01 - 10 citationsIdiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.Evan Lang, Brenda Sande, Samantha Brodkin, Frits van Rhee
Therapeutic Advances in Hematology. 2022-01-01 - 14 citationsA Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine CancersJohanna C. Bendell, Ahmed Zakari, Evan Z. Lang, David M. Waterhouse, Douglas Flora
Cancer Investigation. 2016-04-29
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
